A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight loss and diabetes management) – confirms it also lowers the risk of major heart problems in people who are overweight or obese and already have heart disease , even if they don’t have diabetes. Importantly, this heart protection happens regardless of how much weight a person loses or their baseline body weight, according to the new study, published in The Lancet.

The SELECT trial originally studied over 17,000 adults with heart disease and a body mass index (BMI) of 27 or higher, comparing semaglutide to a placebo. This new analysis looked closely at how patients’ weight and waist size changed during the tr

See Full Page